Kitazawa R, Kitazawa S
Acta Histochem Cytochem. 2025; 58(1):1-8.
PMID: 40060361
PMC: 11886596.
DOI: 10.1267/ahc.24-00056EP.
Zang H, Liu T, Wang X, Cheng S, Zhu X, Huang C
J Immunother Cancer. 2025; 13(3).
PMID: 40050045
PMC: 11887316.
DOI: 10.1136/jitc-2024-010529.
Tang X, Dang S, Qiu J, Zhou R, Ling J, Zhang L
Front Mol Biosci. 2025; 12:1530253.
PMID: 40017628
PMC: 11864935.
DOI: 10.3389/fmolb.2025.1530253.
Kato Y
Int J Clin Oncol. 2025; .
PMID: 39985645
DOI: 10.1007/s10147-025-02721-5.
Zhao B, Xuan R, Yang G, Hu T, Chen Y, Cai L
Discov Oncol. 2025; 16(1):212.
PMID: 39976877
PMC: 11842676.
DOI: 10.1007/s12672-025-01889-6.
Immune Resistance in Glioblastoma: Understanding the Barriers to ICI and CAR-T Cell Therapy.
Eckert T, Zobaer M, Boulos J, Alexander-Bryant A, Baker T, Rivers C
Cancers (Basel). 2025; 17(3).
PMID: 39941829
PMC: 11816167.
DOI: 10.3390/cancers17030462.
Gut IgA functionally interacts with systemic IgG to enhance antipneumococcal vaccine responses.
Gutzeit C, Grasset E, Matthews D, Maglione P, Britton G, Miller H
Sci Adv. 2025; 11(7):eado9455.
PMID: 39937896
PMC: 11817949.
DOI: 10.1126/sciadv.ado9455.
Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy.
Shi J, Zhang Z, Chen H, Yao Y, Ke S, Yu K
Mol Ther. 2025; 33(3):1073-1090.
PMID: 39905727
PMC: 11897759.
DOI: 10.1016/j.ymthe.2025.01.047.
Granulomatous inflammatory responses are elicited in the liver of PD-1 knockout mice by genome mutagenesis.
Nagaretnam I, Kakimoto Y, Yoneshige A, Takeuchi F, Sakimura T, Sato K
Discov Immunol. 2025; 4(1):kyae018.
PMID: 39839810
PMC: 11744370.
DOI: 10.1093/discim/kyae018.
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.
Eshaq A, Flanagan T, Ba Abbad A, Makarem Z, Bokir M, Alasheq A
Int J Mol Sci. 2025; 26(1.
PMID: 39795946
PMC: 11719825.
DOI: 10.3390/ijms26010088.
Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature.
Yang G, Tian L, Wang Y
Discov Oncol. 2025; 16(1):12.
PMID: 39760792
PMC: 11703795.
DOI: 10.1007/s12672-025-01749-3.
Immunoadjuvant therapy in the regulation of cell death in sepsis: recent advances and future directions.
Islam M, Watanabe E, Salma U, Ozaki M, Irahara T, Tanabe S
Front Immunol. 2024; 15:1493214.
PMID: 39720718
PMC: 11666431.
DOI: 10.3389/fimmu.2024.1493214.
Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.
Hosseininejad-Chafi M, Eftekhari Z, Oghalaie A, Behdani M, Sotoudeh N, Kazemi-Lomedasht F
Med Oncol. 2024; 42(1):36.
PMID: 39719469
DOI: 10.1007/s12032-024-02588-y.
Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy.
Godiyal Y, Maheshwari D, Taniguchi H, Zinzuwadia S, Morera-Diaz Y, Tewari D
Mil Med Res. 2024; 11(1):82.
PMID: 39690423
PMC: 11654217.
DOI: 10.1186/s40779-024-00586-9.
Harnessing m1A modification: a new frontier in cancer immunotherapy.
Wang X, Ma X, Chen S, Fan M, Jin C, Chen Y
Front Immunol. 2024; 15:1517604.
PMID: 39687616
PMC: 11647001.
DOI: 10.3389/fimmu.2024.1517604.
Predicting and Monitoring Immune Checkpoint Inhibitor Therapy Using Artificial Intelligence in Pancreatic Cancer.
Yu G, Zhang Z, Eresen A, Hou Q, Amirrad F, Webster S
Int J Mol Sci. 2024; 25(22).
PMID: 39596108
PMC: 11593706.
DOI: 10.3390/ijms252212038.
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.
Wu Y, Sun X, Kang K, Yang Y, Li H, Zhao A
J Hematol Oncol. 2024; 17(1):106.
PMID: 39511607
PMC: 11542428.
DOI: 10.1186/s13045-024-01621-x.
Exosome therapeutics for non-small cell lung cancer tumorigenesis.
Orooji N, Fadaee M, Kazemi T, Yousefi B
Cancer Cell Int. 2024; 24(1):360.
PMID: 39478574
PMC: 11523890.
DOI: 10.1186/s12935-024-03544-6.
Astragaloside IV augments anti-PD-1 therapy to suppress tumor growth in lung cancer by remodeling the tumor microenvironment.
Wu T, Wu S, Gao H, Liu H, Feng J, Yin G
Eur J Histochem. 2024; 68(4).
PMID: 39440587
PMC: 11558310.
DOI: 10.4081/ejh.2024.4098.
PD-1 expression in tumor infiltrating lymphocytes as a prognostic marker in early-stage non-small cell lung cancer.
Dan A, Aricak O, Rounis K, Montero-Fernandez M, Guijarro R, Ekman S
Front Oncol. 2024; 14:1414900.
PMID: 39391244
PMC: 11464330.
DOI: 10.3389/fonc.2024.1414900.